Table 1 |
|||||
|
Cell lines arranged from most sensitive (low IC50) to least sensitive (high IC50) |
|||||
|
Cell line |
IC50value (nM) |
IC50standard error |
Breast cancer subtype |
ER status |
HER2 status |
|
|
|||||
|
MDA-MB-175 |
4 |
0.4 |
Luminal |
Positive |
Normal |
|
ZR-75-30 |
5 |
0.5 |
Luminal |
Positive |
Amplified |
|
CAMA-1 |
8 |
0.4 |
Luminal |
Positive |
Normal |
|
MDA-MB-134 |
13 |
1.3 |
Luminal |
Positive |
Normal |
|
HCC-202 |
21 |
2.3 |
Luminal |
Positive |
Amplified |
|
UACC-893 |
24 |
1.6 |
Luminal |
Positive |
Amplified |
|
EFM-19 |
27 |
12.3 |
Luminal |
Positive |
Normal |
|
SUM-190 |
28 |
1.3 |
Luminal |
Positive |
Amplified |
|
EFM-192A |
42 |
21.2 |
Luminal |
Positive |
Amplified |
|
MDA-MB-361 |
44 |
4.1 |
Luminal |
Positive |
Amplified |
|
HCC-1500 |
45 |
22.6 |
Luminal |
Positive |
Normal |
|
HCC-1419 |
51 |
3.7 |
Luminal |
Positive |
Amplified |
|
HCC-38 |
64 |
14.8 |
Basal |
Negative |
Normal |
|
MDA-MB-415 |
64 |
6.6 |
Luminal |
Positive |
Normal |
|
MCF-10A |
92 |
0.1 |
n/a |
Negative |
Immortalized |
|
UACC-812 |
96 |
4.6 |
Luminal |
Positive |
Amplified |
|
HCC-2218 |
100 |
17.0 |
Luminal |
Positive |
Amplified |
|
ZR-75-1 |
110 |
54.1 |
Luminal |
Positive |
Normal |
|
MDA-MB-453 |
115 |
1.4 |
Luminal |
Negative |
Amplified |
|
184A1 |
118 |
2.0 |
n/a |
Negative |
Immortalized |
|
T47-D |
127 |
15.0 |
Luminal |
Positive |
Normal |
|
MCF-7 |
148 |
25.7 |
Luminal |
Positive |
Normal |
|
BT-20 |
177 |
3.1 |
Basal |
Negative |
Normal |
|
MDA-MB-435 |
201 |
7.5 |
Post-EMT |
Negative |
Normal |
|
BT-474 |
240 |
64.5 |
Luminal |
Positive |
Amplified |
|
SK-BR-3 |
300 |
83.0 |
Luminal |
Negative |
Amplified |
|
KPL-1 |
327 |
64.3 |
Luminal |
Positive |
Normal |
|
HCC-1143 |
359 |
99.7 |
Basal |
Negative |
Normal |
|
MDA-MB-231 |
432 |
16.1 |
Post-EMT |
Negative |
Normal |
|
HCC-1395 |
472 |
39.8 |
Post-EMT |
Negative |
Normal |
|
SUM-225 |
503 |
55.7 |
Luminal |
Negative |
Amplified |
|
Hs578t |
524 |
12.3 |
Post-EMT |
Negative |
Normal |
|
184B5 |
538 |
41.1 |
n/a |
Negative |
Immortalized |
|
UACC-732 |
744 |
14.9 |
Luminal |
Positive |
Amplified |
|
CAL-51 |
905 |
0.0 |
Post-EMT |
Negative |
Normal |
|
BT-549 |
1,000 |
n/a |
Post-EMT |
Negative |
Normal |
|
COLO-824 |
1,000 |
n/a |
Basal |
Negative |
Normal |
|
DU4475 |
1,000 |
n/a |
Basal |
Negative |
Normal |
|
HCC-1187 |
1,000 |
n/a |
Basal |
Negative |
Normal |
|
HCC-1569 |
1,000 |
n/a |
Post-EMT |
Negative |
Amplified |
|
HCC-1806 |
1,000 |
n/a |
Basal |
Negative |
Normal |
|
HCC-1937 |
1,000 |
n/a |
Post-EMT |
Negative |
Normal |
|
HCC-1954 |
1,000 |
n/a |
Basal |
Negative |
Amplified |
|
HCC-70 |
1,000 |
n/a |
Basal |
Negative |
Normal |
|
MDA-MB-436 |
1,000 |
n/a |
Post-EMT |
Negative |
Normal |
|
MDA-MB-157 |
1,000 |
n/a |
Post-EMT |
Negative |
Normal |
|
MDA-MB-468 |
1,000 |
n/a |
Basal |
Negative |
Normal |
|
|
|||||
|
Included are molecular subtype and estrogen receptor (ER) and HER2 status. Cell lines representing the luminal ER-positive subtype were most sensitive to the growth inhibition effects of PD 0332991. n/a, not applicable; Post-EMT, cell lines classified as representing breast cancers that had undergone an epithelial-to-mesenchymal transition. |
|||||
|
Finn et al. Breast Cancer Research 2009 11:R77 doi:10.1186/bcr2419 |
|||||
